Zobrazeno 1 - 10
of 101
pro vyhledávání: '"Gillian L Hirst"'
Autor:
Heather I. Greenwood, Cristian K. Maldonado Rodas, Rita I. Freimanis, Alexa C. Glencer, Phoebe N. Miller, Rita A. Mukhtar, Case Brabham, Christina Yau, Jennifer M. Rosenbluth, Gillian L. Hirst, Michael J. Campbell, Alexander Borowsky, Nola Hylton, Laura J. Esserman, Amrita Basu
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-9 (2024)
Abstract New approaches are needed to determine which ductal carcinoma in situ (DCIS) is at high risk for progression to invasive ductal carcinoma (IDC). We retrospectively studied DCIS patients who declined surgery (2002–2019), and received endocr
Externí odkaz:
https://doaj.org/article/1470ee587e164affa1e41c9b96a0b37b
Autor:
Tessa G. Steenbruggen, Denise M. Wolf, Michael J. Campbell, Joyce Sanders, Sten Cornelissen, Bram Thijssen, Roberto A. Salgado, Christina Yau, Nick O-Grady, Amrita Basu, Rajith Bhaskaran, Lorenza Mittempergher, Gillian L. Hirst, Jean-Philippe Coppe, Marleen Kok, Gabe S. Sonke, Laura J. van ‘t Veer, Hugo M. Horlings
Publikováno v:
Breast Cancer Research, Vol 25, Iss 1, Pp 1-19 (2023)
Abstract Background Despite major improvements in treatment of HER2-positive metastatic breast cancer (MBC), only few patients achieve complete remission and remain progression free for a prolonged time. The tumor immune microenvironment plays an imp
Externí odkaz:
https://doaj.org/article/cd4ee360474c49639be138517e337159
Autor:
Yiwey Shieh, Jacquelyn Roger, Christina Yau, Denise M. Wolf, Gillian L. Hirst, Lamorna Brown Swigart, Scott Huntsman, Donglei Hu, Jovia L. Nierenberg, Pooja Middha, Rachel S. Heise, Yushu Shi, Linda Kachuri, Qianqian Zhu, Song Yao, Christine B. Ambrosone, Marilyn L. Kwan, Bette J. Caan, John S. Witte, Lawrence H. Kushi, Laura van ‘T Veer, Laura J. Esserman, Elad Ziv
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-11 (2023)
Abstract Aggressive breast cancers portend a poor prognosis, but current polygenic risk scores (PRSs) for breast cancer do not reliably predict aggressive cancers. Aggressiveness can be effectively recapitulated using tumor gene expression profiling.
Externí odkaz:
https://doaj.org/article/138d8faa316e4fb8af5632688f767d95
Autor:
Julie E. Lang, Andres Forero-Torres, Douglas Yee, Christina Yau, Denise Wolf, John Park, Barbara A. Parker, A. Jo Chien, Anne M. Wallace, Rashmi Murthy, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Rachel L. Yung, Claudine Isaacs, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Erica Stringer-Reasor, Elissa Price, Bonnie Joe, Minetta C. Liu, Lamorna Brown-Swigart, Emanuel F. Petricoin, Julia D. Wulfkuhle, Meredith Buxton, Julia L. Clennell, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van ‘t Veer, Nola M. Hylton, Angela M. DeMichele, Donald A. Berry, Laura J. Esserman
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-10 (2022)
Abstract HSP90 inhibitors destabilize oncoproteins associated with cell cycle, angiogenesis, RAS-MAPK activity, histone modification, kinases and growth factors. We evaluated the HSP90-inhibitor ganetespib in combination with standard chemotherapy in
Externí odkaz:
https://doaj.org/article/f1ec1969e2aa401dafdcc1102c26a20e
Autor:
Katharine Yu, Amrita Basu, Christina Yau, Denise M. Wolf, Hani Goodarzi, Sourav Bandyopadhyay, James E. Korkola, Gillian L. Hirst, Smita Asare, Angela DeMichele, Nola Hylton, Douglas Yee, Laura Esserman, Laura van ‘t Veer, Marina Sirota
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionDrug resistance is a major obstacle in cancer treatment and can involve a variety of different factors. Identifying effective therapies for drug resistant tumors is integral for improving patient outcomes.MethodsIn this study, we applied
Externí odkaz:
https://doaj.org/article/c9d670c177794b0ba2003ce13caa9f43
Autor:
Daniela Nachmanson, Adam Officer, Hidetoshi Mori, Jonathan Gordon, Mark F. Evans, Joseph Steward, Huazhen Yao, Thomas O’Keefe, Farnaz Hasteh, Gary S. Stein, Kristen Jepsen, Donald L. Weaver, Gillian L. Hirst, Brian L. Sprague, Laura J. Esserman, Alexander D. Borowsky, Janet L. Stein, Olivier Harismendy
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-13 (2022)
Abstract Microenvironmental and molecular factors mediating the progression of Breast Ductal Carcinoma In Situ (DCIS) are not well understood, impeding the development of prevention strategies and the safe testing of treatment de-escalation. We addre
Externí odkaz:
https://doaj.org/article/25a046ee37fb400db82cd80023557ef6
Autor:
Amy S. Clark, Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, Laura J. van ‘t Veer, Douglas Yee, Stacy L. Moulder, Anne M. Wallace, A. Jo Chien, Claudine Isaacs, Judy C. Boughey, Kathy S. Albain, Kathleen Kemmer, Barbara B. Haley, Hyo S. Han, Andres Forero-Torres, Anthony Elias, Julie E. Lang, Erin D. Ellis, Rachel Yung, Debu Tripathy, Rita Nanda, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Rosa I. Gallagher, Teresa Helsten, Erin Roesch, Cheryl A. Ewing, Michael Alvarado, Erin P. Crane, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Katherine Steeg, Adam Asare, Jeffrey B. Matthews, Scott Berry, Ashish Sanil, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, Richard B. Schwab, W. Fraser Symmans, Nola M. Hylton, Donald A. Berry, Laura J. Esserman, Angela M. DeMichele
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
HER2-targeted therapy improves patient’s outcome in early breast cancer. Here, the authors present the efficacy and biomarker analysis of two HER2-targeted combinations (ado-trastuzumab emtansine plus pertuzumab and paclitaxel, trastuzumab and pert
Externí odkaz:
https://doaj.org/article/e6340916dac6476fac8b24ed5afd32c1
Autor:
Douglas Yee, Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar, Andres Forero-Torres, A. Jo Chien, Anne M. Wallace, Lajos Pusztai, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Kathleen Kemmer, Rachel L. Yung, Paula R. Pohlmann, Debu Tripathy, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Emanuel F. Petricoin, Erica Stringer-Reasor, Carla I. Falkson, Melanie Majure, Rita A. Mukhtar, Teresa L. Helsten, Stacy L. Moulder, Patricia A. Robinson, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Nola M. Hylton, Angela DeMichele, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van‘t Veer, Donald A. Berry, Laura J. Esserman
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
Abstract I-SPY2 is an adaptively randomized phase 2 clinical trial evaluating novel agents in combination with standard-of-care paclitaxel followed by doxorubicin and cyclophosphamide in the neoadjuvant treatment of breast cancer. Ganitumab is a mono
Externí odkaz:
https://doaj.org/article/784de0fabd374658a9d09088fa4a5ee8
Autor:
Mark Jesus M. Magbanua, Wen Li, Denise M. Wolf, Christina Yau, Gillian L. Hirst, Lamorna Brown Swigart, David C. Newitt, Jessica Gibbs, Amy L. Delson, Ekaterina Kalashnikova, Alexey Aleshin, Bernhard Zimmermann, A. Jo Chien, Debu Tripathy, Laura Esserman, Nola Hylton, Laura van ‘t Veer
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
Abstract We investigated whether serial measurements of circulating tumor DNA (ctDNA) and functional tumor volume (FTV) by magnetic resonance imaging (MRI) can be combined to improve prediction of pathologic complete response (pCR) and estimation of
Externí odkaz:
https://doaj.org/article/fc14e93945954cfb88f54bbbdcc007fe
Autor:
Daniela Nachmanson, Joseph Steward, Huazhen Yao, Adam Officer, Eliza Jeong, Thomas J. O’Keefe, Farnaz Hasteh, Kristen Jepsen, Gillian L. Hirst, Laura J. Esserman, Alexander D. Borowsky, Olivier Harismendy
Publikováno v:
BMC Medical Genomics, Vol 13, Iss 1, Pp 1-15 (2020)
Abstract Background Systematic cancer screening has led to the increased detection of pre-malignant lesions (PMLs). The absence of reliable prognostic markers has led mostly to over treatment resulting in potentially unnecessary stress, or insufficie
Externí odkaz:
https://doaj.org/article/1f9e00e7637c4021a342f7e36b39379a